You are here

Our science / Clinical Trials / Find a Trial / NCT00141232

Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes

Back to Search Print Save as PDF Bookmark Trial

NCT00141232

Last updated on February 22, 2019
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Irvine, Ayrshire, KA12 OAY United Kingdom
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Type 2 Diabetes
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- They have a diagnosis of Type 2 Diabetes Mellitus for at least 3 months prior to
entry.

- Are not known to have had a cardiovascular event

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- They are taking prescribed lipid lowering therapy

- Have triglycerides > or = 8.0 mmol/L

NCT00141232
Pfizer
Completed
Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Based on your search, you may also be interested in

Type 2 Diabetes Mellitus
To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.
NCT00143338
All Genders
30+
Years
Multiple Sites
Type 2 Diabetes Mellitus
A Phase 1 Study In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy
NCT02292433
All Genders
20+
Years
Hachioji-shi, Tokyo
Type 2 Diabetes Mellitus
Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes
NCT01285518
All Genders
30+
Years
Multiple Sites
Type 2 Diabetes Mellitus (T2DM)
Multiple Dose Study Of PF-05231023 In Obese Adult Subjects
NCT01923389
All Genders
21+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now